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• Diffuse large B-cell lymphoma (DLBCL) is an aggressive 
B-cell malignancy that can be categorized by cell of 
origin, molecular features and reoccurring mutations. 
• The transcription factor “NF-κB” plays a key role in cell 
survival, inflammation and immune responses; in cancer 
it promotes malignant cell proliferation.
• Targeting pathways such as the  NF-κB is a viable 
option to treat B-cell malignancies. 
• A novel NF-κB inhibitor was evaluated in DLBCL cell 
lines (OCI-LY3, RI-1, and Pfeiffer). 
• The NF-κB inhibitor showed cytotoxic effects in DLBCL 
cells, especially those dependent on NF-κB.
NF-κB-i decreased DLBCL cell proliferation  
especially for the ABC cell lines with the RI-1 
cell line having the lowest IC50. 
ABC-DLBCL cell lines are more dependent on 
NF-kB signaling compared to GBC which may 
be the reason why our novel NF-κB-i had a 
greater anti-proliferative effects (~2-6 folds). 
This approach may be promising to treat 
DLBCL, especially more aggressive subtype. 
Future studies are needed to validate the 
drugs mechanism of action and preclinical 
efficacy. 
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Methodology
Cell Proliferation Assay
• MTS assay is a colorimetric method used to determine the 
number of viable cells in proliferation using a tetrazolium salt 
(MTS). 
• Cells that are metabolically active will convert the MTS salt into a 
purple formazan product.
• The amount of formazan measured at 490 nm absorbance is 
directly proportional to the number of living/proliferating cells.
• To determine half maximal inhibitory concentration (IC50) of drug-
of-interest, cells are treated with various amounts of  
drug/inhibitor starting from high concentration to low (i.e., serial 
dilution).
• After drug treatment, the MTS salt solution is added, and 
absorbance is measured on a plate reader 3-4 hours later.
• To evaluate the effects of our novel NF-κB inhibitor (NF-κB-i), 
GBC- and ABC-DLBCL cell lines were treated with NF-κB-i for 72 
hours and cell proliferation was measured by MTS assay.
Introduction
DLBCL
• DLBCL is the most common type of non-
Hodgkin lymphoma in adults, with an 
annual incidence > 25,000 cases.
• Patients have enlarged lymph nodes in the neck, groin, or 
abdomen with abundant infiltrating B-cells.
• The most common treatment is chemoimmunotherapy 
such as R-CHOP, which has a 5-year survival rate of 58%.
• DLBCL is clinically heterogeneous in part due to the 
diversity in gene expression and/or molecular features.
• Based on cell of origin, there are two prominent subtypes 
of DLBCL (85% of cases): geminal center B-cell “GBC-
DLBCL” and activated B-cell “ABC-DLBCL”.
• These subtypes have distinct gene signatures/molecular 
patterns indicating different stages of B-cell differentiation 
and activation.
• ABC-DLBCL are characterized with active B-cell receptor-
dependent NF-κB signaling.
• These molecular differences between GBC and ABC-
DLBCL subtypes translate to clinical differences, with ABC-











NF- B-i Concentration ( M)
Pfeiffer (IC50= 1.21  0.290 M)
OCI-LY3 (IC50= 0.51  0.082 M)
RI-1 (IC50= 0.24  0.082 M)
ABC-DLBCL cell line
GBC-DLBCL cell line
• Experiments repeated 3 times per cell line.
• Dotted line represents IC50 value.
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